Mary P. McGowan

3.1k citations

46 papers · 2.1k indexed · 2 hit papers · h-index 16

Endocrinology, Diabetes and Metabolism top 2%
- Diabetes, Cardiovascular Risks, and Lipoproteins 10
Surgery top 2%
- Lipoproteins and Cardiovascular Health 39
Cancer Research top 5%
- Cancer, Lipids, and Metabolism 8
Cardiology and Cardiovascular Medicine top 5%
- Lipid metabolism and disorders 7
- Antiplatelet Therapy and Cardiovascular Diseases 2
Economics and Econometrics top 2%
- Health Systems, Economic Evaluations, Quality of Life 13
- Pharmaceutical Economics and Policy 8
Public Health, Environmental and Occupational Health
- Health and Medical Research Impacts 6

Co-authors: Patrick M. Moriarty Matthew K. Ito Daniel J. Rader Sarah D. de Ferranti Anne C. Goldberg Christie M. Ballantyne William C. Cromwell Peter P. Tóth
Cited by: Endocrinology, Diabetes and Metabolism Surgery Cancer Research
Partner nations: United States United Kingdom Netherlands

In The Last Decade

Mary P. McGowan

44 papers receiving 2.0k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2011 Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
2011 Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

Peers

Countries citing papers authored by Mary P. McGowan

Since Specialization

Citations

This map shows the geographic impact of Mary P. McGowan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary P. McGowan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary P. McGowan more than expected).

Fields of papers citing papers by Mary P. McGowan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary P. McGowan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary P. McGowan. The network helps show where Mary P. McGowan may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mary P. McGowan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mary P. McGowan Line = papers co-authored together Mary P. McGowan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Novel strategies to FIND people living with genetic dyslipidemias: The family heart foundation flag, identify, network, and deliver (FIND) familial hypercholesterolemia collaborative learning network Shoshana H. Bardach,George Blike,Laurence Sperling,Kain Kim,Benjamin L. S. Furman,David Kulp,Shivani Lam,Danny J. Eapen,Jennifer A. Orr,Kerrilynn C. Hennessey,Mary P. McGowan,Amit V. Khera,Martha Gulati,Zahid Ahmad,Taylor Triana,Brian S. Mittman,Katherine Wilemon	2025	0
2	Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database Diane MacDougall,Anne Tybjærg-Hansen,Joshua W. Knowles,Theresa Stern,Bonnie Hartsuff,Mary P. McGowan,Seth J. Baum,Katherine Wilemon,Børge G. Nordestgaard	2025	8
3	A novel outreach approach for identification of familial hypercholesterolemia: Interview-based formative evaluation to improve healthcare access and quality Rachel C Forcino,Terry Sturke,Mary P. McGowan,Amanda N. Perry,Shoshana H. Bardach,Vikrant Vaze,Kerrilynn C. Hennessey	2025	1
4	Implementation of a machine learning model and direct-to-patient outreach program for targeted screening for familial hypercholesterolemia Kerrilynn C. Hennessey,Shoshana H. Bardach,Terry Sturke,Vikrant Vaze,Roshni Kalkur,Adam Prince,Hanyuan Shi,Marc Hofley,Peter Chin,Rachel C Forcino,Mary P. McGowan	2025	1
5	IMPACT-FH Study for Implementing Innovative Family Communication and Cascade Testing Strategies for Familial Hypercholesterolemia Laney K. Jones,Gemme Campbell‐Salome,Nicole Walters,Andrew Brangan,Kelly Morgan,Eric P. Tricou,Zoe T Lindsey Mills,Mary P. McGowan,Samuel S. Gidding,Alicia Johns,H. Lester Kirchner,Alanna Kulchak Rahm,Amy C. Sturm	2024	4
6	Innovative Implementation Strategies for Familial Hypercholesterolemia Cascade Testing: The Impact of Genetic Counseling Kelly Morgan,Gemme Campbell‐Salome,Nicole Walters,Megan Betts,Andrew Brangan,Alicia Johns,H. Lester Kirchner,Zoe Lindsey‐Mills,Mary P. McGowan,Eric P. Tricou,Alanna Kulchak Rahm,Amy C. Sturm,Laney K. Jones	2024	2
7	Utilizing innovative implementation strategies for familial hypercholesterolemia: Implementation outcomes from the IMPACT-FH study Gemme Campbell‐Salome,Kelly Morgan,Jazmine Gabriel,Mary P. McGowan,Nicole Walters,Andrew Brangan,Eric P. Tricou,Alanna Kulchak Rahm,Amy C. Sturm,Laney K. Jones	2024	3
8	A qualitative study of perceptions of the care pathway for familial hypercholesterolemia: screening, diagnosis, treatment, and family cascade screening Amy R. Pettit,Tamar Klaiman,Rebecca Connelly Kersting,Christina Johnson,Nkiru Ogbuefi,Maeve Moran,Kate Sinclair,Jenna Steckel,Laurie Norton,Jennifer A. Orr,Allyson Lieberman,Mary P. McGowan,Eric P. Tricou,Jinbo Chen,Daniel J. Rader,Kevin G. Volpp,Rinad S. Beidas	2024	1
9	Family cascade screening for equitable identification of familial hypercholesterolemia: study protocol for a hybrid effectiveness-implementation type III randomized controlled trial Christina Johnson,Jinbo Chen,Mary P. McGowan,Eric P. Tricou,Mary Card,Amy R. Pettit,Tamar Klaiman,Daniel J. Rader,Kevin G. Volpp,Rinad S. Beidas	2024	2
10	Lipoprotein(a): An important piece of the ASCVD risk factor puzzle across diverse populations Nicole Ciffone,Catherine J. McNeal,Mary P. McGowan,Keith C. Ferdinand	2023	7
11	Acceptability, Appropriateness, and Feasibility of Automated Screening Approaches and Family Communication Methods for Identification of Familial Hypercholesterolemia: Stakeholder Engagement Results from the IMPACT-FH Study Laney K. Jones,Nicole Walters,Andrew Brangan,Catherine D. Ahmed,Michael H. Gatusky,Gemme Campbell‐Salome,Ilene Ladd,Amanda Sheldon,Samuel S. Gidding,Mary P. McGowan,Alanna Kulchak Rahm,Amy C. Sturm	2021	12
12	A proof-of-concept study of cascade screening for Familial Hypercholesterolemia in the US, adapted from the Dutch model Mary P. McGowan,Marina Cuchel,Catherine D. Ahmed,Amit V. Khera,William S. Weintraub,Katherine Wilemon,Zahid Ahmad	2021	17
13	Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan	2013	23
14	Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy Mary P. McGowan,Jean‐Claude Tardif,R Češka,Lesley Burgess,Handrean Soran,Ioanna Gouni‐Berthold,Gilbert Wagener,Scott Chasan-Taber	2012	176
15	APOLIPOPROTEIN B SYNTHESIS INHIBITION BY MIPOMERSEN REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL WHEN ADDED TO MAXIMALLY TOLERATED LIPID-LOWERING MEDICATION IN PATIENTS WITH SEVERE HETEROZYGOUS HYPERCHOLESTEROLEMIA Jean‐Claude Tardif,Mary P. McGowan,R Češka,Lesley Burgess,Handrean Soran,Ioanna Gouni‐Berthold,Gilbert Wagener,Scott Chasan-Taber	2011	14
16	Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patientsbreakdown → Anne C. Goldberg,Paul N. Hopkins,Peter P. Tóth,Christie M. Ballantyne,Daniel J. Rader,Jennifer G. Robinson,Stephen R. Daniels,Samuel S. Gidding,Sarah D. de Ferranti,Matthew K. Ito,Mary P. McGowan,Patrick M. Moriarty,William C. Cromwell,Joyce L. Ross,Paul Ziajka	2011	465
17	Management of Familial Hypercholesterolemias in adult patients: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia Matthew K. Ito,Mary P. McGowan,Patrick M. Moriarty	2011	99
18	Abstract 19931: Mipomersen, An Apolipoprotein B Synthesis Inhibitor, Reduces Small LDL Particle Number and Increases LDL Particle Size in Patients with Heterozygous Familial Hypercholestrolemia and Coronary Artery Disease William C. Cromwell,Robert Dufour,Claude Gagné,Daniel Gaudet,Cara East,Joanne M. Donovan,Wai Chin,Diane L. Tribble,Mary P. McGowan	2010	2
19	NLA Symposium screening and treatment of familial hypercholesterolemia: How can we do better? Opening and introductions Mary P. McGowan	2010	2
20	Primary Testicular Choriocarcinoma with Pulmonary Metastases Presenting as ARDS Mary P. McGowan,Melvin R. Pratter,Gerard B. Nash	1990	11

About Mary P. McGowan

Mary P. McGowan is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Economics and Econometrics, having authored 46 papers that have together received 2.1k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (39 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (10 papers), Cancer, Lipids, and Metabolism (8 papers), Pharmaceutical Economics and Policy (8 papers), Lipid metabolism and disorders (7 papers), Health and Medical Research Impacts (6 papers) and Antiplatelet Therapy and Cardiovascular Diseases (2 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (714 citations), Surgery (1.6k citations) and Cancer Research (461 citations). Mary P. McGowan has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Patrick M. Moriarty, Matthew K. Ito, Daniel J. Rader, Sarah D. de Ferranti, Anne C. Goldberg, Christie M. Ballantyne, William C. Cromwell, Peter P. Tóth, Paul Ziajka and Stephen R. Daniels.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact